Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial Marina Chiara Garassino , Olga Martelli , Massimo Broggini +17 more 2013 The Lancet Oncology 475 citations